Figure 4
Validation in tissue samples of downregulation of PI3K/mTOR pathway signaling and reduction in cell proliferation under XL765 treatment. (A) Cropped western blots of phosphorylated 4E-BP1, 4E-BP1 and β-actin for tissues from control and XL765-treated mice. Complete blots can be seen in Supplementary Fig. 4. (B) Quantification of 4E-BP1, p4E-BP1 and their ratio (p4E-BP1/4E-BP1). Data are normalized to β-actin level. (C) Immunohistochemical analysis of control and XL765‐treated U87IDHmut tumors. Expression of Ki-67 for each treatment group at the end of the study. All histological images are the same magnification (×20). (D) Quantification Ki-67 positive cells normalized to total number of cells. Dark purple bar: Control; Light purple bar: XL765-treated. *p < 0.05, **p < 0.01, ***p < 0.001.
